JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Cerrado

SectorSanidad

185.78 1.25

Resumen

Variación precio

24h

Actual

Mínimo

185.31

Máximo

185.87

Métricas clave

By Trading Economics

Ingresos

27M

330M

Ventas

104M

5.3B

P/B

Media del Sector

33.913

38.156

BPA

3.35

Rentabilidad por dividendo

2.23

Margen de beneficios

6.259

Empleados

70,000

EBITDA

93M

546M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+8.32% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.23%

2.50%

Próximas Ganancias

7 ago 2025

Fecha Próximo Dividendo

30 sept 2025

Próxima Fecha de Ex Dividendo

8 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-15B

50B

Apertura anterior

184.53

Cierre anterior

185.78

Noticias sobre sentimiento de mercado

By Acuity

16%

84%

20 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Becton Dickinson and Co Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 jul 2025, 14:26 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 jul 2025, 11:08 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 jul 2025, 10:37 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1 may 2025, 11:18 UTC

Ganancias

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15 jul 2025, 18:32 UTC

Adquisiciones, fusiones, absorciones

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Adquisiciones, fusiones, absorciones

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 jul 2025, 16:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 jul 2025, 15:06 UTC

Adquisiciones, fusiones, absorciones

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 jul 2025, 14:11 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 jul 2025, 10:53 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 jul 2025, 10:22 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 jul 2025, 10:22 UTC

Adquisiciones, fusiones, absorciones

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 jul 2025, 10:22 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 jul 2025, 10:21 UTC

Adquisiciones, fusiones, absorciones

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 jul 2025, 10:20 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 jul 2025, 10:19 UTC

Adquisiciones, fusiones, absorciones

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 jul 2025, 10:19 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 jul 2025, 10:18 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 jul 2025, 10:18 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 jul 2025, 10:17 UTC

Adquisiciones, fusiones, absorciones

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 jul 2025, 10:16 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 jul 2025, 10:16 UTC

Adquisiciones, fusiones, absorciones

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 jul 2025, 10:15 UTC

Adquisiciones, fusiones, absorciones

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 jul 2025, 10:15 UTC

Adquisiciones, fusiones, absorciones

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1 may 2025, 10:33 UTC

Ganancias

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 may 2025, 10:33 UTC

Ganancias

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 may 2025, 10:32 UTC

Ganancias

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 may 2025, 10:32 UTC

Ganancias

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 may 2025, 10:31 UTC

Ganancias

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 may 2025, 10:31 UTC

Ganancias

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Comparación entre iguales

Cambio de precio

Becton Dickinson and Co previsión

Precio Objetivo

By TipRanks

8.32% repunte

Estimación a 12 Meses

Media 200.73 USD  8.32%

Máximo 255 USD

Mínimo 172 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Becton Dickinson and Co Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

4

Comprar

9

Mantener

0

Vender

Puntuación técnica

By Trading Central

167 / 206.99Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

20 / 375 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.